Breaking News Instant updates and real-time market news.

NKTR

Nektar

$22.11

6.61 (42.65%)

05:54
03/21/17
03/21
05:54
03/21/17
05:54

Nektar price target raised to $24 from $18 at JPMorgan

JPMorgan analyst Jessica Fye raised her price target for Nektar Therapeutics to $24 citing the positive phase III results for NKTR-181 in pain. The analyst sees a "strong probability" that Nektar partners the drug through the rest of phase III development and to commercialization. She keeps an Overweight rating on the shares.

  • 29

    Mar

  • 01

    Apr

NKTR Nektar
$22.11

6.61 (42.65%)

01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
03/20/17
ROTH
03/20/17
NO CHANGE
Target $31
ROTH
Buy
Roth Capital raises Nektar price target to $31 after 'impressive' opioid data
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
03/21/17
JEFF
03/21/17
NO CHANGE
Target $25
JEFF
Buy
Nektar price target raised to $25 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Nektar Therapeutics to $25 citing the "unexpected" Phase 3 success for NKTR-181. In a research note tiled "NKTR-181 Back From the Dead; Could Become a Major Product in Chronic Pain," Steinberg says the drug could become the company's largest and most profitable product since it directly addresses the "opioid epidemic." NKTR-181 could bring "significant value" to Nektar as early as 2020, the analyst contends. Steinberg adds that the company now fits his takeover thesis. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

AXE

Anixter

$78.85

0.5 (0.64%)

06:37
07/25/17
07/25
06:37
07/25/17
06:37
Hot Stocks
Anixter sees FY17 organic sales growth up 3.0%-5.0% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CIT

CIT Group

$48.90

-0.09 (-0.18%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Earnings
CIT Group reports Q2 operating EPS ex-items 68c, consensus 60c »

Reports Q2 revenue $605M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TSLA

Tesla

$342.52

14.12 (4.30%)

, FB

Facebook

$166.00

1.57 (0.95%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Hot Stocks
Musk says Zuckerberg's knowledge of artificial intelligence 'limited' »

In response to a tweet…

TSLA

Tesla

$342.52

14.12 (4.30%)

FB

Facebook

$166.00

1.57 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 02

    Aug

  • 08

    Aug

  • 13

    Sep

  • 02

    Oct

BIIB

Biogen

$284.70

1.78 (0.63%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Hot Stocks
Biogen announces updated strategic framework »

Biogen announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

, POAHY

Porsche

$5.82

-0.03 (-0.51%)

06:35
07/25/17
07/25
06:35
07/25/17
06:35
Periodicals
VW CEO criticizes Porsche labor chief's remarks on Audi, Reuters says »

Volkswagen (VLKAY) CEO…

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

POAHY

Porsche

$5.82

-0.03 (-0.51%)

AUDVF

Audi AG

$835.60

-4.8 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$78.85

0.5 (0.64%)

06:35
07/25/17
07/25
06:35
07/25/17
06:35
Earnings
Anixter reports Q2 adjusted EPS $1.36, consensus $1.34 »

Reports Q2 revenue $2.0B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

AEL

American Equity

$28.06

0.06 (0.21%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Downgrade
American Equity rating change  »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

TRMB

Trimble

$38.20

0.49 (1.30%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Hot Stocks
Trimble adds first partner in Latin America to Vantage network »

Trimble announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 14

    Aug

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Hot Stocks
Supervalu sees FY18 net earnings from continuing operations $51M-$70M »

Sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BIIB

Biogen

$284.70

1.78 (0.63%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Biogen raises FY17 adjusted EPS view to $20.80-$21.40 from $20.45-$21.25 »

FY17 consensus $20.38.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GPK

Graphic Packaging

$13.77

0.04 (0.29%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Graphic Packaging reports Q2 adj. EPS 15c, consensus 15c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Hot Stocks
Breaking Hot Stocks news story on PulteGroup »

PulteGroup believes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
Supervalu reports Q1 adjusted EPS 9c, consensus 11c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MORE

Monogram Residential Trust

$11.95

0.01 (0.08%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Downgrade
Monogram Residential Trust rating change  »

Monogram Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
PulteGroup reports Q2 adjusted EPS 47c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TEAM

Atlassian

$36.41

0.66 (1.85%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Upgrade
Atlassian rating change  »

Atlassian upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

BIIB

Biogen

$284.70

1.78 (0.63%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Earnings
Biogen reports Q2 adjusted EPS $5.04, consensus $4.41 »

Reports Q2 revenue $3.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GOOG

Alphabet

$980.34

7.42 (0.76%)

, GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Recommendations
Alphabet, Alphabet Class A analyst commentary  »

Alphabet earnings…

GOOG

Alphabet

$980.34

7.42 (0.76%)

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Hot Stocks
Eli Lilly will pursue new standard-of-care changing therapies in oncology »

Eli Lilly is providing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:29
07/25/17
07/25
06:29
07/25/17
06:29
Earnings
Eli Lilly raises FY17 EPS view to $4.10-$4.20 from $4.05-$4.15, consensus $4.12 »

Raises FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

, BMWYY

BMW

$30.72

-0.8 (-2.54%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Periodicals
Daimler directors to discuss alleged German auto cartel, Reuters says »

Daimler's (DDAIF)…

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

BMWYY

BMW

$30.72

-0.8 (-2.54%)

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

POAHY

Porsche

$5.82

-0.03 (-0.51%)

AUDVF

Audi AG

$835.60

-4.8 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$29.20

-0.35 (-1.18%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Upgrade
Werner rating change  »

Werner upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TNTR

Tintri

$6.95

0.16 (2.36%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Tintri initiated  »

Tintri initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$20.85

0.13 (0.63%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Byline Bancorp initiated  »

Byline Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:26
07/25/17
07/25
06:26
07/25/17
06:26
Earnings
Eli Lilly reports Q2 EPS $1.11, consensus $1.05 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.